Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of
 oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic
 benefit of oritavancin administered as a single 1200 mg IV dose.
This is a Phase 3, multicenter, randomized, double-blind, parallel, comparative efficacy and
 safety study of single-dose IV oritavancin/IV placebo versus IV vancomycin for 7 to 10 days
 in adults with acute bacterial skin and skin structure infection (ABSSSI) suspected or proven
 to be caused by Gram-positive pathogens. Approximately 960 patients will be randomized at 100
 centers globally.

 In addition, this study will characterize the PK and PK/PD properties of a single 1200 mg IV
 dose of oritavancin and evaluate the potential health economic benefits offered by this
 dosing strategy.
Inclusion Criteria:

 Subjects may be included in the study if they meet all of the following inclusion criteria:

 1. Males or females ≥18 years old

 2. Diagnosis of ABSSSI suspected or confirmed to be caused by a Gram-positive pathogen
 requiring at least 5 days of IV therapy

 3. An ABSSSI includes one of the following infections Wound infections,
 Cellulitis/erysipelas, Major cutaneous abscess

 4. ABSSSI must present with at least 2 signs and symptoms

 5. Able to give informed consent and willing to comply with all required study procedures

 Exclusion Criteria:

 Subjects will be excluded from the study if any of the following exclusion criteria apply
 prior to randomization:

 1. Prior systemic or topical antibacterial therapy with activity against suspected or
 proven Gram-positive pathogens within the preceding 14 days

 -  The causative Gram-positive pathogen(s) isolated from the ABSSSI site is
 resistant in vitro to the antibacterial(s) that was administered with documented
 clinical progression, or

 -  Documented failure to previous ABSSSI antibiotic therapy is available.
 Documentation of treatment failure must be recorded

 -  Patient received a single dose of a short acting antibacterial therapy three or
 more days before randomization

 2. Infections associated with, or in close proximity to, a prosthetic device

 3. Severe sepsis or refractory shock

 4. Known or suspected bacteremia at time of screening

 5. ABSSSI due to or associated with any of the following:

 -  Infections suspected or documented to be caused by Gram-negative pathogens --
 Wound infections (surgical or traumatic) and abscesses with only Gram-negative
 pathogens

 -  Diabetic foot infections

 -  Concomitant infection at another site not including a secondary ABSSSI lesion

 -  Infected burns

 -  A primary infection secondary to a pre-existing skin disease with associated
 inflammatory changes

 -  Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular
 disease

 -  Any evolving necrotizing process gangrene or infection suspected or proven to be
 caused by Clostridium species

 -  Infections known to be caused by a Gram-positive organism with a vancomycin MIC
 >2 μg/mL or clinically failing prior therapy with glycopeptides

 -  Catheter site infections

 6. Allergy or intolerance to aztreonam or metronidazole in a patient with suspected or
 proven polymicrobial wound infection involving Gram-negative and/or anaerobic bacteria

 7. Currently receiving chronic systemic immunosuppressive therapy

 8. AIDS with CD4 count < 200 cells/mm3

 9. Neutropenia

 10. Significant or life-threatening condition that would confound or interfere with the
 assessment of the ABSSSI

 11. Women who are pregnant or nursing

 12. History of immune-related hypersensitivity reaction to glycopeptides

 13. Patients that require anticoagulant monitoring with an aPTT

 14. Contraindication to vancomycin

 15. Patients unwilling to forego blood and/or blood product donation

 16. Treatment with investigational medicinal product within 30 days before enrollment and
 for the duration of the study

 17. Investigational device present, or removed <30 days before enrollment, or presence of
 device-related infection

 18. Patients unlikely to adhere to the protocol, comply with study drug administration, or
 complete the clinical study

 19. Severe hepatic disease

 20. Presence of hyperuricemia

 21. Unwilling to refrain from chronic use of any medication with antipyretic properties